{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:31:21Z","timestamp":1725582681082},"reference-count":22,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Aim: The main goal is to assess the levels of comorbid diseases and examine the changes in D-dimer in hospitalized patients before and following SC enoxaparin medication.\nMaterial and Methods: At the Al-Yarmouk Teaching Hospital in Baghdad, Iraq, from October 2022 to May 2023, 86 patients who were hospitalized and had severe to critical COVID-19 infections provided data for a retrospective analysis.\nResults: The medical records of all COVID-19 patients who were hospitalized and whose D-dimer level was greater than 0.5 mg\/l and who were given enoxaparin (40 mg subcutaneously) were reviewed with the requisite authorization from the relevant authorities. The D-dimer level was assessed following therapy on the day of admission and day five after commencing enoxaparin. An examination of 86 case records revealed that persons with COVID-19 had significantly decreased D-dimer levels after taking subcutaneous enoxaparin (p-value&lt;0.0001). The comorbidities (diabetes mellitus, hypertension) of patients who received the drug were compared.\nConclusions: Enoxaparin and other anticoagulants were utilized to treat the coagulopathy brought on by COVID-19. Low molecular weight heparin enoxaparin has demonstrated positive outcomes in the management of VTE. A decrease in D-dimer level is anticipated when COVID-19 patients are treated with subcutaneous enoxaparin, partly because decreased coagulation results in lower fibrin formation.<\/jats:p>","DOI":"10.36740\/wlek202404131","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:30:31Z","timestamp":1718307031000},"page":"828-833","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Enoxaparin on D-dimer levels in hospitalized Corona Virus patients with a comparison of its level in patients with comorbid conditions"],"prefix":"10.36740","volume":"77","author":[{"given":"Maysaa Ali Abdul","family":"Khaleq","sequence":"first","affiliation":[{"name":"DEPARTMENT OF PHARMACY, AL-MAARIF UNIVERSITY COLLEGE, AL-ANBAR, IRAQ,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033-40, doi: 10.1182\/blood.2020006000.","DOI":"10.1182\/blood.2020006000"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Yousef P, Sultana S, Siri G, Rezaian SA, Ghulam A, Zofran A et al. Coagulopathy and thromboembolic events a pathogenic mechanism of COVID-19 associated with mortality: An updated review. J Clin Lab Anal. 2023 Jun;37(11-12):e24941, doi: 10.1002\/jcla.24941.","DOI":"10.1002\/jcla.24941"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang WM, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273, doi: 10.1038\/s41586-020-2012-7.","DOI":"10.1038\/s41586-020-2012-7"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Liu P, Blet A, Smyth D, Li H. The Science Underlying COVID-19. Circulation. 2020;142(1):68-78, doi: 10.1161\/CIRCULATIONAHA.120.047549.","DOI":"10.1161\/circulationaha.120.047549"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Talasaz A, Sadeghipour P, Kakavand H, et al. Recent Randomized Trials of Antithrombotic Therapy for Patients with COVID-19. J Am Coll Cardiol. 2021;77(15):1903-1921, doi: 10.1016\/j.jacc.2021.02.035.","DOI":"10.1016\/j.jacc.2021.02.035"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Hemost. 2020;18(4):844-847, doi: 10.1111\/jth.14768.","DOI":"10.1111\/jth.14768"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Guan WJ, Ni ZY, Hu Y, et.al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engle J Med. 2020 Apr 30;382(18):1708-1720, doi: 10.1056\/NEJMoa2002032.","DOI":"10.1056\/NEJMoa2002032"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046, doi: 10.1136\/bmjopen-2017-017046.","DOI":"10.1136\/bmjopen-2017-017046"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost 2020;26:107602962093814.50","DOI":"10.1177\/1076029620938149"},{"key":"ref9","unstructured":"10. COVID-19 Clinical management: living guidance. Who. int. 2021 https:\/\/www.who.int\/publications\/i\/item\/WHO -2019-nCoVclinical-2021-1 [Access: August 2023]."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thrombosis and Hemostasis. 2020;120(06): 998-1000, doi: 10.1055\/s-0040-1710018.","DOI":"10.1055\/s-0040-1710018"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Porfidia A, Pola R. Venous thromboembolism in COVID-19 patients. J Thromb Haemost. 2020; 18(6):1516-1517, doi:10.1111\/jth.14842.","DOI":"10.1111\/jth.14842"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, et al. Open SAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Nature. 2020;584:430-436, doi: 10.1038\/s41586-020-2521-4.","DOI":"10.1101\/2020.05.06.20092999"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS. COVID-19 severity is tripled in the diabetes community: A prospective analysis of the pandemic\u2019s impact in type 1 and type 2 diabetes. Diabetes Care. 2021;44:526-532, doi: 10.2337\/dc20-2260.","DOI":"10.2337\/dc22-er05c"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Sharma P, Behl T, Sharma N, Singh S, Grewal AS, Albarrati A, Albratty M, Meraya AM, Bungau S. COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality. Biomed Pharmacotherapy. 2022; 151: 113089, doi: 10.1016\/j.biopha.2022.113089.","DOI":"10.1016\/j.biopha.2022.113089"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Delalia D, Jug J, Prkan I..Arterial hypertension following COVID-19: A retrospective study of patients in a central European tertiary care center. Acta Clin Croat. 2022;61(Supply 1):23-27, doi: 10.20471\/acc.2022.61. s1.03","DOI":"10.20471\/acc.2022.61.s1.03"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Chen X, Hu W, Ling J, et al. MedRxiv; 2020. Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients.","DOI":"10.1101\/2020.03.22.20040774"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Trump S, Lukassen S, Anker MS, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. 2021;39:705-716.","DOI":"10.1038\/s41587-020-00796-1"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130:304-309.","DOI":"10.20452\/pamw.15272"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. He X, Yao F, Chen J, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Scientific Reports. 2021;11(1):1830","DOI":"10.1038\/s41598-021-81300-w"},{"key":"ref20","unstructured":"21. Sharp K, Ghodke B. D-dimer Levels in COVID-19 Patients and Its Correlation with Age and Gender: A Retrospective Analysis. Inter J Res Rev. 2020;7(7):339-347."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Ugur M, Adiyeke E, Recep E, Bakan N, Yiyit N. Aggressive thrombi prophylaxis improves clinical process and decreases the need for Intensive Care Unit in Covid-19. Pak J Med Sci. 2021 May-Jun; 37(3): 668\u2013674, doi: 10.12669\/pjms.37.3.3687","DOI":"10.12669\/pjms.37.3.3687"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T17:52:26Z","timestamp":1725558746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/dl\/i\/pdf\/607\/2c367ce7d2d51208eab3df9a9e8e5cd7\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202404131","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"type":"print","value":"0043-5147"}],"subject":[],"published":{"date-parts":[[2024]]}}}